FACIT (Fight Against Cancer Innovation Trust) — Full Portfolio

Acquired by Fluidigm/Standard BioTools.

Acquired by Trillium Therapeutics.

Fusion Pharma develops targeted alpha therapeutics for cancer treatment using proprietary linker technology to connect alpha-emitting medical isotopes to cancer-targeting molecules, delivering lethal damage to tumor cells while minimizing toxicity to healthy tissues.

BiotechHealthtechMedical Devices

Hyivy Health develops a holistic pelvic health device that treats, monitors, tracks, and helps prevent pelvic floor symptoms, along with connecting patients to clinicians and pelvic floor therapists.

Digital HealthFemTechHealthtechMedical Devices

Rachel Bartholomew(CEO & Founder)Kamyar Rounidej(Former Co-founder & first Chief Technical Officer)

KA Imaging develops X-ray imaging technologies and detectors, including dual-energy radiography and phase contrast micro-CT systems, serving medical, veterinary, scientific research, and industrial quality control markets.

Deep TechHardwareMedical DevicesWaterloo, CA

Vancouver

Caroline Stout(Director)Bernard Lam(Executive Officer)Kamran Alam(Executive Officer)Ulrik Nielsen(Director)Heather Lee(Director)Emily Titus(Executive Officer)

Privacy Analytics provides data privacy and regulatory compliance technology and services for organizations seeking to safely manage and use sensitive personal data.

Data & InfrastructureEnterprise SoftwareHealthtech

QurCan Therapeutics develops nanoparticle drug delivery technology called TERP to create nanomedicines for cancer and central nervous system diseases, with a focus on improving tissue targeting and reducing toxicity associated with existing approaches.

BiotechDeep TechMedical Devices

Radialis develops the Radialis PET Imager, an organ-targeted positron emission tomography system for high-resolution medical imaging of specific tissues and organs.

Deep TechHealthtechMedical Devices

Wayne SchnarrAlla ReznikAndrew DeanCarmel ShieldsPeyvand Melati

Radiant Biotherapeutics develops a platform of therapeutic molecules called Multabodies that engage multiple disease targets simultaneously within a single engineered protein to treat cancer and infectious diseases.

BiotechMedical Devices

Arthur Fratamico(Executive Officer, Promoter)Deborah Geraghty, Ph.D.(President and Chief Executive Officer)

BiotechNew York, US

Jose Manuel Otero(Executive Officer)Robert Gould(Director)Jane Henderson(Executive Officer)Michael Burgess(Executive Officer)Stefan Larson(Director)Patrick Machado(Director)

BiotechNobleton

Zaid Atto(Executive Officer)